Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2011

View Archived Issues

Phase II trial investigates SPD-503 in new indication

Genmab achieves milestone in collaboration with Lundbeck

Putative biomarker in non-cystic fibrosis bronchiectasis identified

Scientists at AstraZeneca present new therapy for AML

Malaria vaccine is safe and immunogenic in phase Ib study

Dual dopamine D2 receptor/NET inhibitors identified by Astellas Pharma

Novel glucocorticoid receptor agonist shows anti-inflammatory activity

New dipeptidyl peptidase 4 inhibitors patented by Chinese company

Novel p140-TrkA inhibitors prepared by Array BioPharma

Scientists at Mitsubishi Tanabe Pharma disclose new GPR119 receptor agonists

Abilify approved in Canada for use in new patient population

Dainippon Sumitomo Pharma presents novel amide derivatives

Merck & Co. synthesizes new PRCP inhibitors

Merck & Co. and Roche begin clinical collaboration for HCV infection

Phase II AX-200 study does not meet endpoints

Galapagos announces proof-of-mechanism milestone in alliance with GSK

Phase III study begins for ALKS-9070

New fenofibrate products launched in Japan for hyperlipidemia

Pharmasset to amend design of phase IIb PSI-938 trial

FDA approves Advate for new indication

CHMP issues recommendation on marketing authorization Esmya

Roche's Zelboraf receives CHMP opinion

ISTA Pharmaceuticals declines Valeant's acquisition offer

LabCorp acquires Orchid Cellmark

Zalicus begins phase I Z-944 study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...